Alan Forrest
#166,161
Most Influential Person Now
Alan Forrest's AcademicInfluence.com Rankings
Alan Forrestmedical Degrees
Medical
#3422
World Rank
#3890
Historical Rank
Pharmacology
#429
World Rank
#482
Historical Rank

Alan Forrestphilosophy Degrees
Philosophy
#9792
World Rank
#13402
Historical Rank
Logic
#6749
World Rank
#8296
Historical Rank

Download Badge
Medical Philosophy
Alan Forrest's Degrees
- PhD Pharmacology University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Alan Forrest Influential?
(Suggest an Edit or Addition)Alan Forrest's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients (1993) (1114)
- Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia (2004) (874)
- Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections (2004) (717)
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients (2011) (647)
- Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. (2007) (636)
- Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy (1998) (526)
- Letter: Procaine and malignant hyperthermia. (1974) (421)
- Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing (2010) (373)
- Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. (2004) (352)
- Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. (2013) (324)
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme (2003) (274)
- Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia (2007) (231)
- Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. (1985) (201)
- A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. (2000) (188)
- Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. (2000) (164)
- Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection (2007) (162)
- Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model (2010) (155)
- Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program (2003) (154)
- Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? (2016) (147)
- Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. (1997) (142)
- Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin (1993) (137)
- Dosing Guidance for Intravenous Colistin in Critically Ill Patients (2016) (129)
- Absolute oral bioavailability of ciprofloxacin (1986) (122)
- Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. (2007) (121)
- Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model (2010) (119)
- Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? (2016) (117)
- Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula (2011) (111)
- Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2011) (111)
- Vancomycin AUC24/MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization (2011) (103)
- Factors Associated With Postoperative Infection (2001) (103)
- Coadministration of Milk Thistle and Indinavir in Healthy Subjects (2003) (101)
- Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. (1991) (98)
- Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. (2016) (96)
- The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2012) (92)
- Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2013) (91)
- Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection (2009) (89)
- Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa (2008) (88)
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model (2013) (87)
- Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. (2009) (85)
- Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. (2005) (85)
- Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline (2011) (85)
- Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. (1987) (83)
- Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin (2004) (83)
- Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. (1998) (82)
- Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid (2014) (81)
- The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. (2002) (80)
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials (2003) (78)
- The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. (1992) (77)
- Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia (2009) (75)
- Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers (1985) (74)
- Multiple-dose pharmacokinetics of imipenem-cilastatin (1984) (74)
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates (2003) (73)
- An evaluation of optimal sampling strategy and adaptive study design (1988) (72)
- Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. (2003) (71)
- Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans (2006) (70)
- A limited sampling strategy for cyclophosphamide pharmacokinetics. (1989) (69)
- Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function (1987) (69)
- Dosing Guidance for Intravenous Colistin in Critically Ill Patients. (2016) (68)
- Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling (2015) (68)
- Use of adaptive control with feedback to individualize suramin dosing. (1992) (66)
- Pharmacokinetics and Pharmacodynamics of Midazolam After Intranasal Administration (1997) (66)
- Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance (2016) (65)
- Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. (2001) (64)
- Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs (1999) (64)
- Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (1999) (63)
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane (2013) (62)
- Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. (1986) (60)
- Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii (2017) (60)
- Dose ranging study and constant infusion evaluation of ciprofloxacin (1986) (58)
- A Gentamicin Pharmacokinetic Population Model and Once‐Daily Dosing Algorithm for Neonates (2003) (58)
- Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Ciprofloxacin Than for Cefmenoxime (1994) (56)
- Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers (1998) (56)
- Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. (2013) (55)
- Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens (2016) (54)
- Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. (2001) (54)
- Pharmacodynamic interactions of antibiotics alone and in combination. (1998) (54)
- Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi (2005) (54)
- Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors (2005) (54)
- Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. (2015) (54)
- Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients (2017) (54)
- Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use (2015) (53)
- Effect of dose size on bioavailability of ciprofloxacin (1987) (52)
- Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype (2008) (50)
- Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm (2018) (50)
- Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. (2011) (50)
- Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model (2015) (48)
- Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events (2008) (48)
- Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia (2009) (48)
- AUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval (1996) (47)
- Erratum: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore (Clinical Infectious Diseases (2007) 44, (79-86)) (2007) (46)
- Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). (1989) (43)
- Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. (2007) (43)
- Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition (2012) (42)
- Pharmacokinetics and bioavailability of fluconazole in patients with AIDS (1993) (42)
- Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate (1989) (41)
- Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. (2003) (41)
- Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia (2010) (41)
- Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity (2017) (41)
- Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations (2005) (41)
- Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. (2011) (40)
- Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation: Selecting the Best Antimicrobial Dose to Treat an Infection (2010) (40)
- Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants (1995) (40)
- Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii (2016) (39)
- Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model (2013) (39)
- Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model (2017) (38)
- Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. (2000) (38)
- Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii (2016) (38)
- Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination (1986) (37)
- Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. (2002) (37)
- High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii (2017) (35)
- Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia (2011) (35)
- A prospective evaluation of optimal sampling theory in the determination of the steady‐state pharmacokinetics of piperacillin in febrile neutropenic cancer patients (1989) (34)
- Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. (2016) (34)
- Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance (2012) (33)
- A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients (2008) (33)
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model (2016) (32)
- In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. (2008) (32)
- Predictors of agr Dysfunction in Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates among Patients with MRSA Bloodstream Infections (2011) (32)
- Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. (2012) (32)
- The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function (2006) (32)
- Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia (2013) (31)
- New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease (2013) (31)
- Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus (2012) (31)
- Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models (2016) (31)
- Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients (1987) (31)
- Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. (2010) (30)
- Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia (2013) (30)
- In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. (1997) (29)
- Comparison of the Plasma, Urine and Blister Fluid Pharmacokinetics of Clarithromycin and Azithromycin in Normal Subjects (1997) (28)
- Oral administration of fomepizole produces similar blood levels as identical intravenous dose (2008) (28)
- Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients (2011) (27)
- Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. (1987) (27)
- Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. (2000) (26)
- Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women (2012) (25)
- Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies (2013) (25)
- Weight-based heparin dosing: clinical response and resource utilization. (1998) (25)
- Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks (2007) (24)
- Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii (2015) (24)
- Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. (2016) (24)
- Sex‐Related Differences in the Pharmacokinetics of Oral Ciprofloxacin (2004) (24)
- The Utility of Acute Physiology and Chronic Health Evaluation II Scores for Prediction of Mortality among Intensive Care Unit (ICU) and Non-ICU Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia (2012) (23)
- Clinical Experience With Linezolid in Conjunction With Wound Coverage Techniques for Skin and Soft-Tissue Infections and Postoperative Osteomyelitis (2004) (22)
- Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers (1986) (22)
- Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies (2014) (22)
- The Pharmacodynamics of Sumatriptan in Nitroglycerin‐Induced Headache (1999) (22)
- Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study (2013) (21)
- Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. (2008) (20)
- Prospective use of optimal sampling theory: Steady‐state ciprofloxacin pharmacokinetics in critically ill trauma patients (1989) (20)
- Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections (2014) (19)
- Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. (2013) (19)
- Insulin use, adipokine profiles and breast cancer prognosis (2017) (19)
- Effect of Aging on Atenolol Pharmacokinetics and Pharmacodynamics (1995) (19)
- Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics (2013) (19)
- Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects (2003) (19)
- Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population (2012) (18)
- Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. (2003) (18)
- Controlled randomized group comparison of nomifensine and imipramine in depressive illness. (1977) (18)
- Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime (1996) (18)
- Using machine learning to optimise antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. (2020) (17)
- 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF) (2011) (17)
- Effect of renal function on the bioavailability of ciprofloxacin (1990) (17)
- Relationships between renal function and disposition of oral ciprofloxacin (1988) (17)
- Assessment and modelling of antibacterial combination regimens. (2017) (16)
- Ciprofloxacin pharmacokinetics in critically ill trauma patients. (1989) (16)
- Pharmacokinetic modeling of recombinant interleukin‐2 in patients with human immunodeficiency virus infection (1998) (16)
- Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers (1997) (16)
- Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naive, Human Immunodeficiency Virus-Infected Subjects (2004) (16)
- SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles (2005) (16)
- Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. (2016) (15)
- Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring (2007) (15)
- Evaluation of a Sparse Sampling Strategy for Determining Vancomycin Pharmacokinetics in Preterm Neonates: Application of Optimal Sampling Theory (1997) (15)
- Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae (2019) (14)
- Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use. (2019) (14)
- Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis. (2006) (14)
- Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. (2011) (14)
- Modeling the response of pneumonia to antimicrobial therapy (1997) (13)
- Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model (2007) (13)
- Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats (2017) (13)
- Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model (2017) (13)
- Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals (2005) (13)
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model (2017) (13)
- Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. (1991) (13)
- Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (13)
- Approaches to optimal dosing of hexamethylene bisacetamide (2004) (13)
- Eprosartan Does Not Affect the Pharmacodynamics of Warfarin (1998) (13)
- Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa (2018) (13)
- Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia (2013) (13)
- Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. (2007) (12)
- Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. (2014) (12)
- Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. (2000) (12)
- Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. (1996) (12)
- Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans (2000) (12)
- Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients (1985) (12)
- A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity (2013) (11)
- Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers (1987) (11)
- Multiple-dose activate charcoal as adjunct therapy after chronic phenytoin intoxication. (1991) (11)
- In Pursuit of the triple Crown: mechanism-based pharmacodynamic modeling for the optimization of 3-drug combinations against KPC-Producing Klebsiella pneumoniae. (2020) (11)
- Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection (2001) (11)
- Optimal Sampling Theory: Effect of Error in a Nominal Parameter Value on Bias and Precision of Parameter Estimation (1994) (11)
- Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. (2003) (11)
- Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations (2016) (11)
- New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae (2017) (11)
- Critical Need for Clarity in Polymyxin B Dosing (2017) (11)
- Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis (1994) (10)
- Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa (2019) (10)
- The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers (1984) (10)
- Patterns of Prescribing ACE Inhibitors after Myocardial Infarction (1999) (10)
- Effect of saturable clearance during high-dose mezlocillin therapy (1984) (10)
- Effect of Concomitant Administration of Cimetidine Hydrochloride on the Pharmacokinetic and Safety Profile of Tamsulosin Hydrochloride 0.4 mg in Healthy Subjects (2002) (10)
- Optimizing use of quinolones in the critically ill. (2007) (9)
- Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation (2002) (9)
- Pharmacodynamic Variability beyond That Explained by MICs (2013) (9)
- Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design (2015) (8)
- Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers (2008) (8)
- Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics (2013) (8)
- Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists. (2007) (8)
- Effects of the concomitant administration of tamsulosin (0·8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects: a placebo‐controlled evaluation (2002) (8)
- Relationship of Linezolid Minimum Inhibitory Concentration and Time to Bacterial Eradication in Treatment for Methicillin-Resistant Staphylococcus Aureus Infection (2008) (8)
- Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need. (2006) (7)
- Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers (2016) (7)
- The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models (2013) (7)
- Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. (2006) (7)
- Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy (2016) (7)
- Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558) (1991) (6)
- In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model. (2017) (6)
- Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders (2011) (6)
- Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model (2019) (5)
- Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach (2016) (5)
- Polymyxins for the treatment of lower respiratory tract infections; lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. (2021) (5)
- Circulating adipokines data associated with insulin secretagogue use in breast cancer patients (2016) (5)
- Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis. (2011) (5)
- Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers (2015) (5)
- Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells (2015) (5)
- The Population Pharmacokinetics of Amphotericin B Colloidal Dispersion in Patients Receiving Bone Marrow Transplants (1999) (5)
- Statin treatment use in diabetic patients with breast cancer: A potential C-reactive protein mediated benefit. (2011) (5)
- Vasoreactivity in Pre‐ and Postmenopausal Women: Evaluation by Pharmacodynamic Modeling (1998) (4)
- TH1 and TH2 cytokines dataset in insulin users with diabetes mellitus and newly diagnosed breast cancer (2017) (4)
- Population PKS & PDS of tamsulosin, in patients with benign prostatic hyperplasia (BPH) (1996) (4)
- Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/Ureidopenicillin Combination Therapy (2012) (4)
- Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen) (1985) (4)
- Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes (2018) (4)
- Correspondence re: M. J. Egorin et al. Pharmacokinetics and Dosage Reduction of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum in Patients with Impaired Renal Function. Cancer Res., 44: 5432–5438, 1984—Reply (1987) (4)
- p16INK4a, a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV‐Infected Subjects (2016) (4)
- Pharmacodynamic Interactions of Ciprofloxacin, Piperacillin, and Piperacillin/Tazobactam in Healthy Volunteers (1998) (4)
- Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables (2006) (4)
- AMGET, an R-Based Postprocessing Tool for ADAPT 5 (2013) (4)
- Advances in pharmacogenomics of antiretrovirals: an update. (2007) (3)
- Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment (2019) (3)
- Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression (2016) (3)
- Population Pharmacokinetics of CEM-102 in Healthy Subjects (2009) (3)
- Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males (2000) (3)
- Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer (2017) (3)
- Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine (2017) (3)
- Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients (2021) (3)
- Compartmental analysis of saquinavir (SQV) pharmacokinetics (PK) (2005) (2)
- Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer (2017) (2)
- Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analysis for Solithromycin to Support Intravenous Dose Selection in Patients with Community-Acquired Bacterial Pneumonia (2012) (2)
- Reply to Pai. (2013) (2)
- Definition and Validation of a Novel Metric of Erythropoiesis‐Stimulating Agent Response in Hemodialysis Patients (2019) (2)
- Polymyxin Combinations against Pseudomonas aeruginosa : Profiling the Time-Course of Synergistic Killing and Prevention of Resistance (2015) (2)
- Predictors of Trough Concentrations of Oral Ciprofloxacin (1993) (2)
- Population Pharmacokinetics of Solithromycin (CEM-101) Using Data from the Plasma and Epithelial Lining Fluid of Healthy Subjects (1986) (2)
- Reply to Corona and Cattaneo. (2017) (2)
- Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer (2017) (2)
- High-dose olanzapine for bipolar depression: proceed with caution. (2014) (2)
- Dataset on growth factor levels and insulin use in patients with diabetes mellitus and incident breast cancer (2017) (2)
- Insulin use, hormone receptor status and hematopoietic cytokines׳ circulation in women with diabetes mellitus and breast cancer (2017) (2)
- PK/PD of pegylated‐liposomal doxorubicin (LD) and the appearance of dermal lesions in dogs (1996) (2)
- Translational Modeling of Antibacterial Agents (2016) (2)
- CEM-102 (Sodium Fusidate) Dosage Regimen Decision Support Using Population Pharmacokinetic (PPK) and Mechanism- Based Pharmacokinetic-Pharmacodynamic (PK-PD) Models (2009) (2)
- Safety and tolerability of multiple doses of imipenem/cilastatin (1985) (2)
- Steady-State SerumPharmacokinetics ofNovobiocin andRifampin Alone andinCombination (1986) (2)
- Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients (2020) (1)
- A new model for bacterial growth & drug effects (1999) (1)
- Modeling of Toxicities Due to Antibiotics (2007) (1)
- Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients (2017) (1)
- Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs (2004) (1)
- Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors (2022) (1)
- BETA BLOCKERS IN THE· ELDERLY (1986) (1)
- Delafloxacin Population Pharmacokinetics and Covariate Exploration (2010) (1)
- Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients (2016) (1)
- Pharmacodynamic interactions of ciprofloxacin , piperacillin , and piperacillin/tazobactam in volunteer subjects (1994) (1)
- Development ofa Population Pharmacokinetic Modeland Optimal Sampling Strategies forIntravenous Ciprofloxacin (1993) (1)
- Prophylaxis and in Patients With Recurrent Ischemic Events Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke (2008) (1)
- Effect of Food on the Pharmacokinetics of (‐) and (+) dOTC When Administered as an Oral Racemate (2002) (1)
- TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer (2017) (1)
- F021: Assessment of current treatment trends in the management of high risk hypertension (2000) (0)
- 398Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures (2014) (0)
- Daunorubicin (DNR) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
- Co-modelling of daunorubicin and daunorubicinol pharmacokinetics (1990) (0)
- Phase I Clinical and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered as a Five-Day Continuous Infusion1 (2006) (0)
- Application of SPLINDID, a Semiparametric, Model-Based Method for Pharmacogenomic Modeling of mRNA Dynamics (2006) (0)
- 487Infections Caused by Enterobacteriaceae Species following Cardiac Surgery: Impact of Polymyxin Resistance on Treatment Outcomes (2014) (0)
- Analysis of cardiovascular drugs as predictors of hospital readmission in heart failure (HF) patients (1996) (0)
- Multiple dose pharmacokinetics pks of po opc 17116 in normal subjects 400 vs 800 mg parallel design (1992) (0)
- 48* Nebulized SLIT™ Amikacin in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection in Serbia and Hungary (2007) (0)
- Changes in coronary sinus and femoral artery blood concentrations of K+, Na+ and Ca2+ following cardiopulmonary bypass surgery (1987) (0)
- Characterization of the Pharmacokinetics-Pharmacodynamics of Tazobactam in 1 Combination with Piperacillin in an In Vitro Infection Model 2 (2016) (0)
- Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naı¨ve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (0)
- Optimal sparse pharmacokinetic (PK) sampling strategies (OSS) for multi‐drug antiretroviral (ARV) regimens (2005) (0)
- Optimal multi‐drug PK sampling strategies (OSS) for efavirenz (EFV) & indinavir (IDV) (2005) (0)
- Pharmacometric modelling of risk factors for MRSA (1997) (0)
- A pharmacometric model for factors in the development of bacterial resistance in acutely ill patients (1997) (0)
- Effect ofRenalFunction on theBioavailability ofCiprofloxacin (1990) (0)
- Ciprofloxacin Eradicates Respiratory Tract Bacteria More Rapidly than Cephalosporins in Patients with Nosocomial Pneumonia (1993) (0)
- Pharmacokinetics andBioavailability ofFluconazole in Patients withAIDS (1993) (0)
- Plasmacidal activity (PCA) in plasma of acute myelocytic leukemia (AML) patients (pts) receiving daunorubicin (DNR) (1989) (0)
- Use of Pharmacokinetics-Pharmacodynamics and Monte Carlo Simulation Analyses to Support Brilacidin Dose Selection for Patients with Acute Bacterial Skin and Skin Structure Infections (2013) (0)
- Ciprofloxacin Breakpoints in Enteric Fever: Time to Revise our Susceptibility criteria (2009) (0)
- Pharmacology Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model B (2006) (0)
- Co-modelling of daunorubicin (D1) and daunorubicinol (D2) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
- Pharmacokinetics ofIntravenously Administered Ciprofloxacin in Patients withVarious Degrees ofRenalFunction (1987) (0)
- Standard (S2S) versus iterative-2 (IT2S) stage population analysis of daunorubicin (D1) and daunorubicinol (D2) pharmacokinetics (1991) (0)
- Abstract LB-329: Use of insulin sensitizers is associated with better hormone-receptor pattern and improved breast cancer outcomes (2012) (0)
- NOTES Steady-State Pharmacokinetics ofImipenem inFebrile Neutropenic Cancer Patients (1987) (0)
- Pharmacodynamics (PD) of sumatriptan (S) in nitroglycerin-(NTG) induced headache (HA) (1997) (0)
- Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model (cid:1) (2007) (0)
- Materials and Methods Pharmacokinetics-Pharmacodynamics of CEM-102 (Sodium Fusidate) Against Streptococcus pyogenes Using In Vitro Pharmacodynamic Models (2009) (0)
- Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition (2012) (0)
- Correspondence Failure of Vancomycin for Treatment of Methicillin- Resistant Staphylococcus aureus Infections (2004) (0)
- Absolute OralBioavailability ofCiprofloxacin (1986) (0)
- Comparison of in vivo uptake of azithromycin (A) vs. clarithromycin (C) into polymorphonuclear leukocytes (PMNS) (1997) (0)
- PK-PD Evaluation of Daptomycin (DAP) Against S. aureus (SA) Strains with Increased MIC Values after DAP Exposure (2008) (0)
- Gastrostomy complications in childhood (2001) (0)
- Abstract LB-421: Diabetes pharmacotherapy: A potential modifier of breast cancer prognosis: Table 1. (2010) (0)
- Relationships between serum, intracellular, and infection site concentrations of macrolide and azalide antibiotics: A theoretical exploration of the concept of white blood cell drug delivery to infection sites (1996) (0)
- Effect ofDoseSize on Bioavailability ofCiprofloxacin (1987) (0)
- PIII‐35 (2006) (0)
- POPULATION PHARMACOKINETIC (PK) MODEL OF MYCOPHENOLIC ACID (MPA) AND ITS METABOLITE— MYCOPHENOLIC ACID GLUCORONIDE (MPAG) IN LONG TERM TRANSPLANT RENAL PATIENTS USING MONTE- CARLO PARAMETRIC EXPECTATION MAXIMIZATION (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan Forrest?
Alan Forrest is affiliated with the following schools: